Brilliant minds at the Center for Biopharmaceuticals are now attempting to rewrite the core function of proteins by making alterations in their molecular backbone, for example. By combining biological and chemical methods, researchers are able to design semi-synthetic proteins with almost no regard to the limitations of nature:
"Proteins can be regulated to perform specific biochemical tasks. We have used a technology that allows us to make changes to the molecular backbone of the protein and have thus created 22 completely new designer proteins on the basis of recognised material. Using advanced chemical-biological methods, we made the minuscule changes to the backbone of one of the most frequently occurring protein domains – a kind of fixed, independent module that features in a range of proteins. We then examined how the designer proteins bind to other proteins in the body, which allowed us to analyse the role of the specific protein domain in the body's vital signal processes," relates Søren W. Pedersen, postdoc.
All the cells in the body communicate via receptor proteins that are located in the cell membrane. This activates proteins inside the cell, causing specific effects which, in turn, stimulate the body to execute a variety of functions.
"Our designer proteins show us precisely how and where a bond is formed. This provides unique molecular understanding of the protein domain and a number of key protein bonds in the organism. For example the designer proteins bind to a range of receptors in the body – receptor interactions that are important targets for pharmaceuticals intended to treat stroke, pain and depression. The new findings mean that in the long term, we will be able to design pharmaceuticals that bind more strongly and more accurately to specific sites in the organism."
The fundamental findings have just been published in the scientific journal Nature Communications.
From 'on/off switch' to 'advanced dimmer'
Pharmaceuticals generally function by binding to a specific receptor that is involved in a given illness process – thus halting the damaging effect. Unfortunately, this strategy often generates side effects as the process simultaneously shuts down a number of beneficial functions. In recent years, interest has therefore arisen in a different strategy in which the pharmaceutical does not affect the receptor directly, but alters the interactions that the receptor has with proteins inside the cell. In other words, instead of simply switching the function of the receptor on and off, the objective is now to control parts of the receptor's effects. It is here that designer proteins can come to play a key role:
"The capacity to manipulate proteins has led to important breakthroughs in biotechnology and biomedicine. Proteins can often target specific processes in the cells with a high degree of accuracy – and at the Center for Biopharmaceuticals we are combining chemical synthesis and biological processes to find out more about the molecular interactions that may be of significance to biological pharmaceuticals," explains Professor Kristian Strømgaard, head of the Center for Biopharmaceuticals at the University of Copenhagen.
Contact:Professor Kristian Strømgaard
It has conventionally been possible to use one of two methods to manufacture human proteins in the laboratory. The first method is biological and involves using gene technology to introduce the gene into single-cell organisms such as bacteria and yeast, or into mammal cells. The alternative is to create a protein chemically, which involves linking the amino acids together one by one until the required peptide or protein has been formed.
Each technology has its advantages and drawbacks. The production of proteins in bacteria and yeast is relatively simple to escalate to industrial scale, but gene technology is limited to the use of the 20 amino acids for which the genes code. The chemical method is not limited to the 20 amino acids, but it is expensive and can only be used to make small proteins containing up to 50 amino acids. Most of the 20,000 proteins in the human body are much larger.
Researchers at the Center for Biopharmaceuticals are combining biology and chemistry to make semi-synthetic proteins. This approach entails making only a part of the protein in bacteria or yeast, while the remaining part is created using chemical synthesis. The two sections are then 'glued together' to form the final designer protein.
Kristian Strømgaard | EurekAlert!
Microscope measures muscle weakness
16.11.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg
Good preparation is half the digestion
16.11.2018 | Max-Planck-Institut für Stoffwechselforschung
Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.
Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
16.11.2018 | Life Sciences
16.11.2018 | Life Sciences
16.11.2018 | Physics and Astronomy